Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for FINGOLIMOD
- Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
- Fingolimod for Type 2 Diabetes Mellitus
- Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
- The Objective of This Study is to Compare the Oral Bioavailability and Characterize the Pharmacokinetic Profile
- A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
- Revascularization Pretreated With Fingolimod in Acute Stroke
- Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke
- Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
- Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).
- Fingolimod in Endovascular Treatment of Ischemic Stroke
- Investigation of Inflammation Using [C-11]-CS1P1
- Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
- Fingolimod in COVID-19
- Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
- Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy
- Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer
- Simvastatin in Secondary Progressive Multiple Sclerosis
- Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod
- Melatonin in Patients With Multiple Sclerosis (MS).
- Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
- A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
- Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke
- Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
- Methylprednisolone During the Switch Between Natalizumab and Fingolimod
- Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
- Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
- Effect of Fingolimod on Neurodegeneration
- A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
- Fingolimod Effect on Cytokine and Chemokine Levels
- Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya
- Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
- A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
- Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
- Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
- Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
- Efficacy and Safety of FTY720 for Acute Stroke
- Safety and Efficacy of Fingolimod in MS Patients in China
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
- Gilenya in Amyotrophic Lateral Sclerosis (ALS)
- Fingolimod in Schizophrenia Patients
- Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
- Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
- MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
- Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
- Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
- ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
- STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
- A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
- Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
- Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
- Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
- Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
- A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
- Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
- Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
- Fingolimod -Response According to Coping - Evaluation
- Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
- Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
- Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
- The Gilenya Pregnancy Registry
- Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
- Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
- Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
- This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
- An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
- Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
- Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
- Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
- Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Clinical trials list
click for details